From AI 'Answering' to 'Acting' — Organizing AI Agent Security in the MCP Era

I have compiled an article organizing how AI usage is changing due to MCP and what kinds of risks are emerging, focusing on ...
Blizzard Watch

The Burning Crusade Classic anniversary realms launch Phase 3.5 on October 22

The Burning Crusade Classic anniversary realms are finally getting the next phase of content on October 22, 2026 at 3pm ...

Is there a time lag between yen depreciation news and price tags? — Correlation strengthens with a 9 to 11-month shift

Have you ever wondered why supermarket price tags don't seem to move in the same way during the same month that news of yen ...
InformatiqueNews.fr

Mistral AI

La start-up française des modèles d’IA ouverts et commerciaux, figure de proue de l’IA européenne. Google veut rendre Gemini ...
JD Supra

CBP States CAPE Phase 3 Will Deploy on October 6, 2026

U.S. Customs and Border Protection (“CPB”) has notified the Court of International Trade (“CIT”) that Phase 3 of its Consolidated Administration and Processing of Entries (“CAPE”) will deploy on ...

Marvel’s Phase 7 movie slate is hiding in plain sight

Marvel’s release calendar is always subject to change, but the studio’s plans after Secret Wars are becoming easier to read. The MCU’s next era seemingly won’t be built around the same heroes who ...
BioSpace

Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints

While Novartis’ antibody-oligonucleotide conjugate failed to significantly improve hand function in patients with myotonic dystrophy type 1, the asset nevertheless showed signs of clinical activity in ...
Business Wire

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes ...
Medical News Today

Novel mRNA vaccine plus immunotherapy reduces melanoma relapse in phase 3 trial

Different stages of melanoma have a higher risk of the skin cancer coming back after being surgically removed. An experimental therapy developed by Merck and Moderna aims to help lower the recurrence ...
The Motley Fool

Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for Investors.

Patients who received the personalized vaccine alongside Keytruda went longer before their cancer returned, and longer before it spread to distant parts of the body, than patients who received ...
The Business Journals

Moderna's personalized cancer vaccine shows success in Phase 3 trial

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The trial data represents a key ...
Yahoo Finance

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...